DS
Therapeutic Areas
GenSight Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GS010 (lenadogene nolparvovec) | Leber Hereditary Optic Neuropathy (LHON) due to ND4 mutation | Phase 3 |
| GS030 | Retinitis Pigmentosa (RP) | Phase 1/2 |
| Preclinical Programs | Geographic Atrophy in Dry Age-Related Macular Degeneration (Dry-AMD) | Preclinical |
Leadership Team at GenSight Biologics
LR
Laurence Rodriguez
Chief Executive Officer
JE
Jan Eryk Umiastowski
Chief Financial Officer
DM
Dr. Magali Taiel
Chief Medical Officer
JS
José-Alain Sahel
Scientific Co-Founder
BR
Botond Roska
Scientific Co-Founder
DN
Dr. Nancy J. Newman
Presenter (Emory University) - Key Opinion Leader associated with trial data